ASTCT Consensus Grading for CAR-T
-
Register
- Non-member - Free!
- Member - Free!
Already registered?
Log in now.
This webinar from October 2019 disccuses the new definitions and grading for CRS and neurotoxicity that more accurately categorize the severity of these toxicities. CAR T cell therapy is considered one of the most promising new treatments for patients battling relapsed and refractory leukemia, lymphoma and other forms of cancer. The assessment and grading of CRS and ICANS have varied considerably across clinical trials, academic studies, and commercial products, which has made it difficult to compare the safety and measure toxicity across all of these settings. This also has hindered the ability of researchers to develop the best strategies to manage these toxicities.
Key:
Complete
Next
Failed
Available
Locked
Webinar
Recorded 10/02/2017
Recorded 10/02/2017
This webinar from October 2019 disccuses the new definitions and grading for CRS and neurotoxicity that more accurately categorize the severity of these toxicities. CAR T cell therapy is considered one of the most promising new treatments for patients battling relapsed and refractory leukemia, lymphoma and other forms of cancer. The assessment and grading of CRS and ICANS have varied considerably across clinical trials, academic studies, and commercial products, which has made it difficult to compare the safety and measure toxicity across all of these settings. This also has hindered the ability of researchers to develop the best strategies to manage these toxicities.
